Mobile App Trial in Older HIV Patients: A Pilot RCT in Spain
A pilot RCT tested whether a smartphone app could improve quality of life and treatment adherence in HIV-positive patients aged 60+.
Summary
As HIV patients age, managing a complex chronic condition becomes harder. This completed Spanish randomized controlled trial enrolled 100 HIV-positive adults aged 60 and older to test whether a dedicated mobile health app could improve their quality of life, treatment adherence, and clinical outcomes over 48 weeks. Half the participants received routine medical care plus access to the app, while the other half received standard care alone. Patient satisfaction and app usability were also assessed at 24 and 48 weeks. The study reflects a broader effort to harness digital health tools for chronic disease management in aging populations — a group increasingly relevant to longevity medicine given that HIV accelerates aspects of biological aging, including cardiovascular disease, cognitive decline, and metabolic dysfunction.
Detailed Summary
HIV infection has been transformed from a fatal diagnosis into a manageable chronic condition, but this success has created a new challenge: an aging HIV population facing accelerated biological aging. Approximately 30% of adults living with HIV in high-income countries are currently aged 50 or older (with earlier projections suggesting this could reach 50% by 2015), and this group experiences elevated rates of cardiovascular disease, neurocognitive impairment, metabolic syndrome, and frailty — conditions central to the longevity medicine conversation.
This pilot randomized controlled trial, sponsored in Spain by Fundación FLS, enrolled 100 HIV-positive adults aged 60 and older. Participants were randomized into two groups: one using a purpose-built mobile health app alongside routine medical care, and a control group receiving standard care only. The study ran from December 2016 to July 2018, with follow-up assessments at 24 and 48 weeks measuring usability, patient satisfaction, quality of life, treatment adherence, and standard clinical parameters.
The trial's premise rests on a well-established challenge in chronic disease management: sustained behavioral change is difficult without ongoing engagement tools. Mobile health apps offer a scalable, low-cost mechanism for real-time patient education, medication reminders, symptom tracking, and provider communication — all potentially relevant to improving adherence and outcomes.
For longevity-focused clinicians, HIV provides a compelling model for studying accelerated aging biology. Chronic viral inflammation, antiretroviral drug toxicity, and immune senescence collectively accelerate aging hallmarks. Digital interventions that improve adherence and self-management may therefore have downstream effects on this accelerated aging phenotype.
However, this summary is based solely on the abstract; full results including specific outcome data and statistical findings are not available here. The pilot scale of 100 participants limits generalizability, and no outcome data are reported in the source. Nonetheless, the trial represents an important early step in validating digital health tools for aging chronic disease populations.
Key Findings
- RCT tested a mobile app versus standard care in HIV patients aged 60+ over 48 weeks.
- Outcomes measured included quality of life, treatment adherence, and clinical lab parameters.
- App usability and patient satisfaction were specifically evaluated at weeks 24 and 48.
- HIV accelerates biological aging, making this population highly relevant to longevity research.
- Digital health tools may offer scalable support for medication adherence in aging chronic disease patients.
Methodology
This was a completed two-arm randomized controlled pilot trial enrolling 100 HIV-positive adults aged 60 or older. The experimental group used a dedicated mobile health app plus routine care; the control group received routine care alone. Outcomes were assessed at baseline, week 24, and week 48.
Study Limitations
This summary is based on the abstract only; specific outcome data, effect sizes, and statistical results are not available. The pilot sample of 100 participants limits statistical power and generalizability. The study was conducted in 2016–2018 and may not reflect current app technology or care standards. The abstract does not specify whether the trial was single- or multi-center.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.